A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT07266441. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-label Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refractory' if does not respond to treatment) who have received at least 3 prior lines of therapy.
Study identification
- NCT ID
- NCT07266441
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 168 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 8, 2026 (Actual)
- Primary completion
- Jun 14, 2027 (Estimated)
- Completion
- Dec 12, 2028 (Estimated)
- Last update posted
- Sep 25, 2026
2026 – 2028
United States locations
- U.S. sites
- 30
- U.S. states
- 19
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| O Neal Comprehensive Cancer Center at UAB | Birmingham | Alabama | 35294 | — |
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| City of Hope | Duarte | California | 91010 | — |
| City of Hope Orange County Lennar Foundation Cancer Center | Irvine | California | 92618 | — |
| Cancer and Blood Specialty Clinic | Los Alamitos | California | 90720 | — |
| University of California San Francisco | San Francisco | California | 94143 | — |
| Rocky Mountain Cancer Centers | Aurora | Colorado | 80012 | — |
| Colorado Blood Cancer Institute | Denver | Colorado | 80218 | — |
| Cancer Specialists of North Florida | Jacksonville | Florida | 32256 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Northside Hospital Cancer Institute | Atlanta | Georgia | 30342 | — |
| Cancer Care Specialists of Central Illinois | O'Fallon | Illinois | 62269 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| Mission Cancer Blood | Waukee | Iowa | 50263 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Rutgers Cancer Institute | New Brunswick | New Jersey | 08901 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28204 | — |
| Cleveland Clinic Foundtation | Cleveland | Ohio | 44195 | — |
| Oncology Associates of Oregon PC Willamette Valley Cancer Institute | Eugene | Oregon | 97401 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | — |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | — |
| Texas Oncology | Austin | Texas | 78705 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Oncology Consultants Texas | Houston | Texas | 77030 | — |
| Texas Oncology - Northeast | Tyler | Texas | 75702 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
| NorthWest Medical Specialties, PLLC | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 41 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07266441, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 25, 2026 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07266441 live on ClinicalTrials.gov.